| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.29 | 4e-08 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.35 | 1e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.16 | 0.0004 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.2 | 0.0006 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.18 | 0.001 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |